aeChem grants DIESSE the exclusive access to its international patent that unlocks an innovative detection method on CHORUS immunoassay platforms

Siena, December 22nd, 2022 – DIESSE Diagnostica Senese is proud to announce the signature of an agreement with aeChem for exclusive access, in a specific therapeutic area, to its international patent that unlocks an innovative detection method on Chorus immunoassay platforms.

Founded in Switzerland at the Geneva Biotech Campus, aeChem is a company committed to providing innovative technologies and engineering solutions useful for developing Personalized Medicine. In the last ten years, aeChem has been leveraging chemistry expertise to provide innovations to in vitro diagnostics. An open innovation approach like the one with aeChem and the Geneva Biotech Campus accelerates DIESSE's commitment to research and development.

"With the patient outcome in mind, my researchers are focused daily on improving the quality of our tests. The chemistry competencies that aeChem will bring to my team through this patent and the correlated technology transfer are essential to make another step ahead in this direction," declares Alessandra
Brogi, R&D Director at DIESSE.

"We are extremely proud of this partnership, allowing aeChem to grow further with a seasoned, well-integrated partner in the in vitro diagnostics space. Moreover, the current partnership with DIESSE is only the beginning, as we value long-standing partnerships. Novel diagnostics leveraging DIESSE's and aeChem's know-how is just around the corner", says Kandaswamy Djano, CEO at aeChem.

This agreement confirms DIESSE's international attitude and commitment to developing innovation that concretely contributes to improved patient management and clinical effectiveness.